Logo image of AVXL

ANAVEX LIFE SCIENCES CORP (AVXL) Stock Fundamental Analysis

NASDAQ:AVXL - Nasdaq - US0327973006 - Common Stock - Currency: USD

8.35  -0.33 (-3.8%)

After market: 8.36 +0.01 (+0.12%)

Fundamental Rating

3

Overall AVXL gets a fundamental rating of 3 out of 10. We evaluated AVXL against 572 industry peers in the Biotechnology industry. While AVXL has a great health rating, there are worries on its profitability. AVXL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVXL has reported negative net income.
AVXL had a negative operating cash flow in the past year.
In the past 5 years AVXL always reported negative net income.
AVXL had a negative operating cash flow in each of the past 5 years.
AVXL Yearly Net Income VS EBIT VS OCF VS FCFAVXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

AVXL has a Return On Assets (-37.48%) which is comparable to the rest of the industry.
AVXL's Return On Equity of -41.92% is fine compared to the rest of the industry. AVXL outperforms 70.87% of its industry peers.
Industry RankSector Rank
ROA -37.48%
ROE -41.92%
ROIC N/A
ROA(3y)-31.3%
ROA(5y)-38.71%
ROE(3y)-34.3%
ROE(5y)-44.93%
ROIC(3y)N/A
ROIC(5y)N/A
AVXL Yearly ROA, ROE, ROICAVXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AVXL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVXL Yearly Profit, Operating, Gross MarginsAVXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

AVXL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AVXL has more shares outstanding
There is no outstanding debt for AVXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVXL Yearly Shares OutstandingAVXL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVXL Yearly Total Debt VS Total AssetsAVXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 29.32 indicates that AVXL is not in any danger for bankruptcy at the moment.
AVXL's Altman-Z score of 29.32 is amongst the best of the industry. AVXL outperforms 95.56% of its industry peers.
AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.32
ROIC/WACCN/A
WACCN/A
AVXL Yearly LT Debt VS Equity VS FCFAVXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.45 indicates that AVXL has no problem at all paying its short term obligations.
AVXL has a Current ratio of 9.45. This is in the better half of the industry: AVXL outperforms 78.69% of its industry peers.
AVXL has a Quick Ratio of 9.45. This indicates that AVXL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.45, AVXL is in the better half of the industry, outperforming 78.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.45
Quick Ratio 9.45
AVXL Yearly Current Assets VS Current LiabilitesAVXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AVXL have decreased by -1.85% in the last year.
EPS 1Y (TTM)-1.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 94.22% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-27.5%
EPS Next 2Y153.25%
EPS Next 3Y155.97%
EPS Next 5Y94.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVXL Yearly Revenue VS EstimatesAVXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
AVXL Yearly EPS VS EstimatesAVXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15 20 25

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

AVXL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 3.64, the valuation of AVXL can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AVXL indicates a rather cheap valuation: AVXL is cheaper than 98.76% of the companies listed in the same industry.
AVXL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.68.
Industry RankSector Rank
PE N/A
Fwd PE 3.64
AVXL Price Earnings VS Forward Price EarningsAVXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVXL Per share dataAVXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

A more expensive valuation may be justified as AVXL's earnings are expected to grow with 155.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y153.25%
EPS Next 3Y155.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVXL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (2/21/2025, 8:02:26 PM)

After market: 8.36 +0.01 (+0.12%)

8.35

-0.33 (-3.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12 2025-02-12/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners35.04%
Inst Owner Change5.7%
Ins Owners3.04%
Ins Owner Change0%
Market Cap708.25M
Analysts82.22
Price Target36.69 (339.4%)
Short Float %28.4%
Short Ratio12.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.61%
Min EPS beat(2)15.96%
Max EPS beat(2)19.26%
EPS beat(4)3
Avg EPS beat(4)8.39%
Min EPS beat(4)-15.86%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)13.42%
EPS beat(12)9
Avg EPS beat(12)10.46%
EPS beat(16)11
Avg EPS beat(16)9.48%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.41%
PT rev (3m)1.41%
EPS NQ rev (1m)10.53%
EPS NQ rev (3m)10.53%
EPS NY rev (1m)-2.92%
EPS NY rev (3m)-2.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.64
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.39
P/tB 6.39
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)2.3
Fwd EY27.49%
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.48%
ROE -41.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.3%
ROA(5y)-38.71%
ROE(3y)-34.3%
ROE(5y)-44.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.45
Quick Ratio 9.45
Altman-Z 29.32
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
EPS Next Y-27.5%
EPS Next 2Y153.25%
EPS Next 3Y155.97%
EPS Next 5Y94.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year369.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.24%
OCF growth 3YN/A
OCF growth 5YN/A